<DrugInformationSummary id="CDR0000803971"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about lisocabtagene maraleucel
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/lisocabtagenemaraleucel">Lisocabtagene Maraleucel</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000778386">lisocabtagene maraleucel</TerminologyLink><GlossaryLink ref="CDR0000803963">lisocabtagene maraleucel</GlossaryLink><USBrandNames><USBrandName>Breyanzi</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>LIH-soh-KAB-tuh-jeen MAR-uh-LOO-sel</TermPronunciation><MediaLink ref="CDR0000805383" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000805384" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Lisocabtagene Maraleucel</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Lisocabtagene maraleucel
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell non-Hodgkin lymphoma</GlossaryTermRef></Strong> (NHL), including the following types:<ItemizedList Style="bullet" id="_4"><ListItem><GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">diffuse large B-cell lymphoma</GlossaryTermRef> (DLBCL)</ListItem><ListItem><GlossaryTermRef href="CDR0000045710" dictionary="Cancer.gov" audience="Patient">high-grade</GlossaryTermRef> B-cell lymphoma</ListItem><ListItem><GlossaryTermRef href="CDR0000777025" dictionary="Cancer.gov" audience="Patient">primary mediastinal large B-cell lymphoma</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000430863" dictionary="Cancer.gov" audience="Patient">follicular lymphoma grade 3B</GlossaryTermRef></ListItem></ItemizedList><Para id="_8">It is used in patients who have received:</Para><ItemizedList Style="bullet" id="_12"><ListItem><GlossaryTermRef href="CDR0000346494" dictionary="Cancer.gov" audience="Patient">first-line</GlossaryTermRef> <GlossaryTermRef href="CDR0000270867" dictionary="Cancer.gov" audience="Patient">chemoimmunotherapy</GlossaryTermRef> that  didn't work or the cancer  came back within the first year of treatment</ListItem><ListItem>first-line chemoimmunotherapy that didn't work or the cancer came back and cannot be treated with <GlossaryTermRef href="CDR0000693540" dictionary="Cancer.gov" audience="Patient">hematopoietic</GlossaryTermRef> <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef></ListItem><ListItem>two lines of <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapy</GlossaryTermRef>, but the cancer did not get better or it came back</ListItem></ItemizedList></ListItem>
   <ListItem><Strong><GlossaryTermRef href="CDR0000641290" dictionary="Cancer.gov" audience="Patient">chronic lymphocytic leukemia or small lymphocytic lymphoma</GlossaryTermRef></Strong> that came back or did not get better  after at least 2 lines of systemic therapy that included a <GlossaryTermRef href="CDR0000811784" dictionary="Cancer.gov" audience="Patient">BTK inhibitor</GlossaryTermRef> and a <GlossaryTermRef href="CDR0000613897" dictionary="Cancer.gov" audience="Patient">BCL2</GlossaryTermRef>
inhibitor¹</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">follicular lymphoma</GlossaryTermRef></Strong> that came back or did not get better after  at least 2 lines of systemic therapy¹</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000445048" dictionary="Cancer.gov" audience="Patient">mantle cell lymphoma</GlossaryTermRef></Strong> that came back or did not get better  after at least 2 lines of systemic therapy that included a BTK inhibitor</ListItem></ItemizedList>
  <Para id="_11">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that lisocabtagene maraleucel provides a clinical benefit in these patients.</Para><Para id="_6">Lisocabtagene maraleucel is only available as part of a special program called Breyanzi REMS (<ExternalRef xref="https://www.breyanzirems.com/">Risk Evaluation and Mitigation Strategies</ExternalRef>).</Para><Para id="_7">Lisocabtagene maraleucel
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Lisocabtagene Maraleucel</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/778386">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.42">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a621017.html">Lisocabtagene Maraleucel</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.43"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.44">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers">Understanding the Risk of Second Cancers After CAR T-Cell Therapy</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy">T-cell Transfer Therapy</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C125192">Find Clinical Trials for Lisocabtagene Maraleucel</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2021-02-26</DateFirstPublished><DateLastModified>2025-01-02</DateLastModified></DrugInformationSummary>
